Introduction
Apoptosis, which is critical for development and tissue homeostasis, is executed by caspases (Adams, 2003) . The 10 or so mammalian caspases include both "effectors" (3, 6, and 7), which efficiently digest vital proteins, and "initiators" (e.g., 2, 8, and 9), which proteolytically activate the effectors. Many cell "stress" stimuli, e.g., cytokine deprivation and genome damage, and developmental cues, trigger a common pathway of caspase activation regulated by the Bcl-2 protein family (Adams, 2003) . Until recently, the sole apical initiator in that pathway was assumed to be caspase-9, which is activated in a complex termed the "apoptosome" by the scaffold protein Apaf-1 and its cofactor cytochrome c . Evidence that the Bcl-2 family regulates permeabilization of mitochondria argued that cytochrome c release and the ensuing caspase-9 activation were central to the "stress" response. For some neuronal cells, this model is supported, as mice lacking Apaf-1 or caspase-9 die perinatally with brain overgrowth caused by a defect in neuronal apoptosis (Adams, 2003) .
The apoptosome is not, however, universally essential for Bcl-2-regulated apoptosis, because certain neuronal (Honarpour et al., 2001) , hematopoietic, and fibroblastoid cells lacking Apaf-1 or caspase-9 readily undergo apoptosis in response to diverse insults and, at least in lymphocytes, that apoptosis requires caspase activity . Hence, there must be apoptotic pathways regulated by the Bcl-2 family that require the activation of caspases other than caspase-9 (Adams, 2003) .
Evidence is also accumulating that certain caspases can contribute to mitochondrial damage and hence may be activated before apoptosome formation (Guo et al., 2002; Lassus et al., 2002; Marsden et al., 2002; Robertson et al., 2002) . In particular, caspase-2 has been implicated in cytochrome c release (Guo et al., 2002; Lassus et al., 2002; Robertson et al., 2002 ) and seems to be necessary for cellular demise in some transformed cell lines (Lassus et al., 2002) . However, because apoptosis is not markedly impaired in caspase-2-deficient mice (Bergeron et al., 1998; , caspase-2 cannot have a major nonredundant role in apoptosis.
These discordant findings might be reconciled if caspase-2 acts redundantly with caspase-9, each activating distinct but converging pathways. If so, loss of both caspases should markedly attenuate apoptosis. We address that hypothesis here by studies on mice lacking both caspases 2 and 9.
Results and discussion
To generate mice lacking both caspases 2 and 9, we first intercrossed animals deficient in caspase-2 with caspase-9 ϩ / Ϫ mice (Kuida et al., 1998) . As expected from the severe caspase-9 Ϫ / Ϫ phenotype (Hakem et al., 1998; Kuida et al., 1998) , intercrosses of the resulting caspase-2 ϩ / Ϫ 9 ϩ / Ϫ mice yielded no weaned progeny lacking caspase-9, irrespective of caspase-2 status (67 progeny genotyped). Mice of all other genotypes appeared at the expected Mendelian ratios and were healthy and fertile (unpublished data).
To investigate whether caspase-2 deficiency exacerbated the neuronal overgrowth characteristic of the caspase-9 deficiency (Hakem et al., 1998; Kuida et al., 1998) , embryos from the intercrosses were examined at E14.5, when all genotypes appeared in the expected ratios. Brain over-growth resembling that previously described and observed in caspase-2 ϩ / ϩ 9 Ϫ / Ϫ littermates ( Fig. 1 ) appeared in 6/11 caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ and 2/5 caspase-2 ϩ / ϩ 9 Ϫ / Ϫ embryos but never in those expressing caspase-9 ( n ϭ 47). All other organs appeared normal. Although the brain abnormalities cannot be quantified, we conclude that caspase-2 loss does not substantially exacerbate the brain phenotype due to caspase-9 deficiency and that other organs develop normally to at least E14.5 without either caspases 2 or 9.
Bcl-2-regulated apoptosis, which is critical for the physiological death of hematopoietic cells (Marsden and Strasser, 2003) , can occur independently of caspase-9 . To study how caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ hematopoietic cells respond to the physiological death cues in healthy mice, C57BL/6-Ly5.1 mice were reconstituted with fetal liverderived hematopoietic stem cells from E14.5 offspring of the intercrosses (Ly5.2 ϩ ). 10 wk later, the thymocytes were all derived from donor (Ly5.2) cells, irrespective of donor genotype (Fig. 2 A) . The absence of caspases 2 and 9 did not augment cell numbers or perturb cell subset composition in the thymus, spleen, lymph nodes, or bone marrow (Fig. 2, B-D; and not depicted). Western blot analysis on reconstituted organs (Fig. S1 , available at http://www.jcb.org/cgi/content/ full/jcb.200312030/DC1) confirmed the absence of cas- pase-2 and/or -9 and revealed no compensatory up-regulation of caspases 1, 3, 6, 7, 8, or 9 . Thus, whereas overexpression of Bcl-2 in the hematopoietic compartment, or absence of its antagonist Bim, promotes cell accumulation (Bouillet et al., 1999; Marsden et al., 2002) , programmed death in that compartment appears unaffected by loss of both caspases 2 and 9.
To explore further whether caspases 2 and 9 are essential for Bcl-2-regulated cell death, we analyzed the responses to diverse cytotoxic insults of donor-derived B and T lymphocytes and CD4 ϩ 8 ϩ thymocytes purified from reconstituted animals. The death on cytokine withdrawal of mature B or T cells, activated T lymphoblasts or thymocytes was unimpaired by the absence of caspase-2, caspase-9, or both ( (Fig. 3 A) . In response to ␥ irradiation (Fig. 3 D; Fig. S2 B) or treatment with dexamethasone, PMA, or etoposide (Fig. S2 , C-H), thymocytes lacking caspase-9 were slightly more resistant than wild-type cells, but concomitant deficiency for caspase-2 provided no additional protection, and the lack of caspase-2 alone had no significant effect. This held over a range of doses of each stimulus (Fig. S2 , B, D, F, H; and not depicted). Thus, in lymphocytes caspase-9 deficiency at most merely slows rather than prevents cell death, and concomitant caspase-2 deficiency does not further reduce the rate.
To explore how loss of caspases 2 and 9 affected cells that were not of hematopoietic origin, we studied embryonic fibroblasts lacking caspase-2, caspase-9, or both. When exposed to etoposide, caspase-9 Ϫ / Ϫ fibroblasts died somewhat more slowly than wild-type cells, but the protection was transient and loss of caspase-2 provided no additional survival advantage (Fig. 3 E) . Thus, caspase-2 deficiency does not delay the death of caspase-9-deficient fibroblasts.
Dying caspase-9-deficient cells display the hallmarks of apoptosis . Concomitant absence of caspase-2 did not prevent apoptosis. Two of its classic features, exposure of phosphatidylserine and DNA fragmentation, appeared in caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ thymocytes subjected to ␥ irradiation (Fig. 4, A and B) . It is likely that effector caspases contributed to their death, because the well-characterized caspase substrates ICAD, spectrin, and gelsolin ( Fig. 4  C, Fig. S3 , A and B, available at http://www.jcb.org/cgi/ content/full/jcb.200312030/DC1) were all processed appropriately, albeit to a lower extent than in dying wild-type cells. ICAD is thought to be processed only by caspases 3 or 7 (McIlroy et al., 1999) ; caspase-3 is required to generate the 41-kD product of gelsolin (Slee et al., 2001) , and although either caspases or calpains can generate the 150-kD fragment of spectrin, only caspases give the 120-kD fragment (Methot et al., 2004) . In dying caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ cells, all three substrates yielded the expected caspase-dependent products (Fig. 4 C; Fig. S3, A and B) . Moreover, the gelsolin processing was ablated in irradiated caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ thymocytes treated with either of two structurally unrelated caspase inhibitors, IDN-1965 (Fig. S3 C) or Q-VD-OPh (not depicted). Thus, caspases are strongly implicated in the death of these cells.
Processing of synthetic as well as physiological caspase substrates is lower in cell lysates lacking caspase-9 . Similarly, with the fluorogenic caspase substrate DEVD-aminomethylcoumarin, dying caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ or caspase-9 Ϫ / Ϫ thymocytes had only ‫ف‬ 10-20% of the DEVDase activity of dying wild-type or caspase-2 Ϫ / Ϫ lysates, but the activity was completely blocked by the caspase inhibitor zVAD-fmk (Fig. S3 D) . It was unaffected by ALLN, a potent inhibitor of calpains and cathepsins, arguing against any contribution of these proteases in processing this caspase substrate.
To further explore whether the death of caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ cells requires caspases, we examined the ability of four chemically distinct caspase inhibitors to impair their death (Fig. 4  F) . Three of them, Q-VD-OPh (Caserta et al., 2003) , IDN-1965, and IDN-6275 (Wu and Fritz, 1999) , delayed apoptosis substantially up to 24 h after dexamethasone treatment of T cells (Fig. 4 D) . zVAD-fmk had a smaller inhibitory effect, probably due to its reportedly inferior stability, membrane permeability, and performance in culture (Nicholson, 1999) . Non-caspase proteases, in particular calpains and cathepsins, have been proposed to contribute to apoptosis in cer- tain circumstances (Jaattela and Tschopp, 2003) . To determine whether either participated in the apoptosis of caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ cells, we tested six inhibitors reported to impair apoptosis under certain conditions: the calpain inhibitors z-VF-CHO and PD150606 (Squier and Cohen, 1997) , a cellpermeable peptide of the natural calpain inhibitor calpastatin (Altznauer et al., 2004) , the dual calpain and cathepsin inhibitors ALLM and ALLN (Ding et al., 2002) , and the selective cathepsin inhibitor z-FG-NHO-Bz-p OMe. In contrast to the caspase inhibitors, none of these inhibitors had any anti-apoptotic activity at doses in the range where others have reported efficacy (Fig. 4 D) , and none cooperated with IDN-1965 to enhance its antagonism of apoptosis (not depicted). Hence, it appears unlikely that either calpains or cathepsins act in tandem with the caspase cascade to cause apoptosis in these cells.
Cytochrome c release in thymocytes seems to depend on caspase activity , and caspase-2 has been implicated in mitochondrial disruption in certain cells (Guo et al., 2002; Lassus et al., 2002; Robertson et al., 2002) . Hence, we examined whether caspase-2 was the sole caspase responsible for mitochondrial damage in thymocytes. Western blotting of fractionated cell lysates revealed that cytochrome c release from mitochondria did not require caspase-2 (Fig. 5 A) . Furthermore, mitochondrial transmembrane potential in dying thymocytes was lost normally in the absence of caspase-2, or both caspases 2 and 9, although its loss in wild-type thymocytes was attenuated by a caspase inhibitor (Fig. 5 B) , as shown previously (BossyWetzel et al., 1998) . Hence, both the release of pro-apoptotic molecules from mitochondria and the loss of mitochondrial transmembrane potential can occur independently of caspases 2 and 9.
Our results strongly implicate caspases in the apoptosis of caspase-2 Ϫ / Ϫ 9 Ϫ / Ϫ cells and thus imply that there is a Bcl-2-regulated and caspase-mediated pathway that does not require either caspase-2 or -9. Which other caspases might be regulated by Bcl-2? As discussed elsewhere (Adams, 2003) , caspases 1, 11, and 12 in mice (or caspases 1, 4, and 5 in humans) are attractive candidates, because, like caspases 2 and 9, their NH 2 -terminal CARD domain could interact with a cognate scaffold to form an apoptosome-like complex. For example, caspase-12, which is implicated in apoptosis induced by ER stress (Nakagawa et al., 2000) and in cytochrome c -independent apoptosis (Morishima et al., 2002; Rao et al., 2002) , forms a large complex on serum starvation (Kilic et al., 2002) . In other systems, caspase-11 (Hisahara et al., 2001; Kang et al., 2002) or caspase-1 (Hilbi et al., 1998; Marsden et al., 2002; Rowe et al., 2002) have been implicated in apoptosis. Hence, in different circumstances, vari- 
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Ϫ/Ϫ cells is antagonized by inhibitors of caspases but not of calpains or cathepsins. Ly5.1 Ϫ Thy1 ϩ mature T lymphocytes from the lymph nodes of reconstituted mice were cultured for 24 h in the presence of 100 nM dexamethasone plus the caspase inhibitors zVAD-fmk, IDN-6275 (6275), IDN-1965 IDN- (1965 , or Q-VD-OPh (Q-VD), the calpain inhibitors z-VF-CHO or PD-150606, a cell permeable peptide of the calpain inhibitor calpastatin, the dual calpain/cathepsin inhibitors ALLM and ALLN or the cathepsin inhibitor z-FG-NHO-Bz-pOMe (zFG-NHO) (each at 50 M). Cell death was quantified by PI staining and FACS analysis. Results represent mean Ϯ SD of at least three independent experiments for each genotype. Vehicle: 0.4% DMSO.
ous combinations of caspases 1, 11, and 12, and perhaps also caspase-8, might act redundantly with caspases 2 and 9 to initiate apoptosis.
Whereas our results with primary lymphocytes and fibroblasts implicate caspases in addition to caspases 2 and 9 in the initiation of apoptosis, the accompanying paper, Ekert et al. (2004) shows that the hallmarks of apoptosis failed to appear when myeloid progenitor cell lines lacking both caspases 2 and 9 were deprived of growth factor, but that programmed cell death still prevented their clonogenic survival. These findings and those with transformed human cell lines (Lassus et al., 2002) can be reconciled with our conclusion that caspases 2 and 9 are not essential for loss of viability per se, if some cell types but not others use these caspases to accelerate apoptotic cell demolition.
Materials and methods

Mice
Caspase-2 ϩ/Ϫ 9 ϩ/Ϫ mice were generated by intercrosses of mice deficient in caspase-2 (129/sv) with caspase-9 ϩ/Ϫ (C57BL/6) mice (Kuida et al., 1998) . Embryos and 3-wk-old mice were genotyped by PCR. Hematopoietic reconstitution was performed as described previously 
Microscopic imaging
All microscopy used either a Stemi SV11 or an Axioplan 2 microscope (Carl Zeiss MicroImaging, Inc. 
Flow cytometry
Cells stained with fluorochrome-or biotin-conjugated surface marker-specific antibodies were analyzed using a FACScan (Becton Dickinson). Live and dead cells were discriminated by staining with 2 g/ml propidium iodide (PI; Sigma-Aldrich). In cell sorting, host-derived (Ly5.1) cells were excluded.
Cell culture
Cells were cultured and T lymphoblasts generated as described previously . Before death assays, the viable cells in stimulated spleen cultures were enriched by centrifugation over Ficoll-Paque Plus (Amersham Biosciences). Embryonic fibroblasts, cultured from E14.5 embryos, were used at early passage (n Ͻ 5).
Cell death assays
For cell death assays, cells were cultured at 0.2-1 ϫ 10 6 cells/ml and treated with dexamethasone (Sigma-Aldrich) at 10 -8 -10 -6 M, ␥ radiation (5 Gy from a 60 Co source), PMA (Sigma-Aldrich) at 0.1-10 ng/ml, or etoposide (VP-16, David Bull Laboratories) at 0.1-100 M. Cell viability was determined by staining with 2 g/ml PI and analysis on a FACScan 
Subcellular fractionation and Western blotting
Subcellular fractionation and Western blotting were performed as described previously .
Online supplemental material
Western blot analysis of thymocytes (Fig. S1 A) and splenocytes (Fig. S1 B) from reconstituted animals demonstrates that no compensatory increase in expression of other caspases was evident in cells lacking caspase-2 and/or caspase-9.
Combined deficiency of caspases 2 and 9 in thymocytes does not prevent apoptosis in response to a variety of death stimuli. Thymocytes were subjected to cytokine withdrawal (Fig. S2 A) , cultured after graded doses of ␥ irradation (Fig. S2 B) , or treated with dexamethasone, PMA, or etoposide (Fig. S2, C-H) . Caspase-2 deficiency did not influence the sensitivity to these stimuli of cells lacking or expressing caspase-9.
Western blotting of thymocytes sorted from reconstituted mice demonstrates that in dying cells the caspase substrates spectrin (Fig. S3 A) and gelsolin (Fig. S3 B) are processed to the expected caspase-generated products. Cell extracts were also made from cells of the indicated genotypes cultured with or without the caspase inhibitor IDN-1965 . Western blotting of these extracts shows the caspase dependence of gelsolin processing in dying cells (Fig. S3 C) . Caspase-like DEVDase activity was measured by fluorogenic assay (Fig. S3 D) . Online supplemental material is available at http://www.jcb. 
